Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PAVM 
PAVmed Inc (PAVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: PAVM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.5
1 Year Target Price $11.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -41.84% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.38M USD | Price to earnings Ratio 0.17 | 1Y Target Price 11.5 |
Price to earnings Ratio 0.17 | 1Y Target Price 11.5 | ||
Volume (30-day avg) 2 | Beta 1.06 | 52 Weeks Range 0.55 - 1.90 | Updated Date 06/30/2025 |
52 Weeks Range 0.55 - 1.90 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.46 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3711.54% | Operating Margin (TTM) -68075% |
Management Effectiveness
Return on Assets (TTM) -49.81% | Return on Equity (TTM) 64.41% |
Valuation
Trailing PE 0.17 | Forward PE - | Enterprise Value 45192771 | Price to Sales(TTM) 5.21 |
Enterprise Value 45192771 | Price to Sales(TTM) 5.21 | ||
Enterprise Value to Revenue 22.68 | Enterprise Value to EBITDA 0.68 | Shares Outstanding 17294600 | Shares Floating 12475682 |
Shares Outstanding 17294600 | Shares Floating 12475682 | ||
Percent Insiders 22.22 | Percent Institutions 7.05 |
Analyst Ratings
Rating 2 | Target Price 11.5 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PAVmed Inc
Company Overview
History and Background
PAVmed Inc. (PAVM) is a medical device company founded in 2014. It focuses on developing and commercializing innovative medical technologies. Initially focused on vascular access, it has expanded into multiple therapeutic areas through internal development and acquisitions.
Core Business Areas
- Veris Health: Veris Health is focused on developing and commercializing digital health solutions for cancer care, including its Oncodiscu2122 portfolio.
- CarpX: CarpX is a minimally invasive carpal tunnel release device designed to reduce recovery time and complications compared to traditional surgery.
- EsoGuard/EsoCheck: EsoGuard is a DNA biomarker test and EsoCheck is a non-endoscopic device used to collect esophageal cells for early detection of Barrett's esophagus.
- PortIO: PortIO is an implantable intraosseous vascular access device for hemodialysis.
Leadership and Structure
Lishan Aklog, M.D. serves as the Chairman and CEO. The company has a standard corporate structure with a board of directors and executive management team leading various departments like R&D, marketing, and finance.
Top Products and Market Share
Key Offerings
- EsoGuard/EsoCheck: EsoGuard is a DNA biomarker test performed on samples collected by EsoCheck, a non-endoscopic cell collection device. Revenue in 2023 was ~$1.8M. Competitors: Exact Sciences (Cologuard), Guardant Health (Guardant360), LabCorp and Quest (Esophageal Biopsies).
- CarpX: CarpX is a single-use, minimally invasive device for carpal tunnel release. Revenue in 2023 was less than $500K. Competitors: Traditional open surgery, endoscopic carpal tunnel release (e.g., Stryker, CONMED).
- Veris Health: Veris Health develops digital health solutions for cancer care, centered around the Oncodisc portfolio, no significant revenues to date. Competitors: Livongo (Teladoc), Omada Health, CancerIQ.
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory hurdles, and intense competition. PAVmed operates in several segments including diagnostics, vascular access, and minimally invasive surgery. These segments are influenced by factors such as aging populations, technological advancements, and healthcare spending.
Positioning
PAVmed aims to disrupt existing medical procedures with less invasive and more cost-effective solutions. Their competitive advantage lies in their innovative technology and streamlined regulatory pathways (e.g., 510(k) clearance).
Total Addressable Market (TAM)
The TAM across PAVmed's target markets is estimated in billions of dollars. EsoGuard/EsoCheck addresses the Barrett's esophagus screening market (est. at >$2 billion). CarpX targets the carpal tunnel release market (est. at >$1 billion). PAVmed aims to capture significant share of these markets with its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative medical device technologies
- Strong intellectual property portfolio
- Experienced management team
- Potential for high growth in target markets
- Streamlined regulatory pathways for some products
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Commercialization challenges
- Relatively small market presence
- History of losses
Opportunities
- Expansion into new markets
- Strategic partnerships and collaborations
- Acquisitions of complementary technologies
- Increasing adoption of minimally invasive procedures
- Positive clinical trial results
Threats
- Competition from larger, established medical device companies
- Regulatory changes
- Product liability claims
- Reimbursement challenges
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- EXAS
- GH
- STRY
- CONM
Competitive Landscape
PAVmed faces intense competition from larger, more established medical device companies with greater financial resources and market access. PAVmed's innovative products have the potential to disrupt the market, but the company needs to overcome significant commercialization challenges.
Growth Trajectory and Initiatives
Historical Growth: PAVmed's historical growth has been slow and inconsistent due to regulatory hurdles and commercialization challenges.
Future Projections: Analyst projections suggest significant revenue growth in the coming years driven by increased adoption of EsoGuard/EsoCheck and CarpX. However, these projections are highly speculative.
Recent Initiatives: Recent initiatives include expanding the commercial sales team for EsoGuard/EsoCheck, strategic focus on Veris Health, and advancing clinical trials for PortIO.
Summary
PAVmed is a struggling company with innovative medical device technologies targeting large markets, but it faces significant financial and commercialization challenges. Its success depends on successful commercialization of EsoGuard/EsoCheck, CarpX, and Veris Health. PAVmed needs to address its financial weaknesses and increase its market presence to compete effectively. There is significant financial risk involved as it needs to continually raise funds to meet operation expenditure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- PAVmed Inc. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information is based on publicly available data, which may be subject to change. Investment decisions should be made based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PAVmed Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2016-04-28 | Chairman & CEO Dr. Lishan Aklog M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 39 | Website https://www.pavmed.com |
Full time employees 39 | Website https://www.pavmed.com | ||
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.